BRPI0408928A - métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente - Google Patents
métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um pacienteInfo
- Publication number
- BRPI0408928A BRPI0408928A BRPI0408928-6A BRPI0408928A BRPI0408928A BR PI0408928 A BRPI0408928 A BR PI0408928A BR PI0408928 A BRPI0408928 A BR PI0408928A BR PI0408928 A BRPI0408928 A BR PI0408928A
- Authority
- BR
- Brazil
- Prior art keywords
- situation
- patient
- apoptotic
- complexes
- methods
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"MéTODOS PARA DETERMINAR UMA SITUAçãO DE DOENçA EM UM PACIENTE, UMA SITUAçãO APOPTóTICA DE CéLULAS EM UMA AMOSTRA, E UMA SITUAçãO DE UM CáNCER EM UM PACIENTE". A invenção fornece um método para determinar uma situação de doença em um paciente medindo-se níveis de expressão de complexos intracelulares selecionados. Em um aspecto da invenção, a situação de ativação de trajetos apoptóticos em uma amostra do paciente é determinada medindo-se quantidades relativas de complexos de proteína-proteína que são característicos dos trajetos apoptóticos. Em particular, a invenção fornece um método para determinar a situação de ativação do trajeto apoptótico mitocondrial medindo-se simultaneamente quantidades relativas de complexos entre proteínas 14-3-3 e proteinas BAD por um lado e complexos de proteínas Bcl-2 e proteínas BAD por outro lado. Preferivelmente, os métodos da invenção são implementados usando-se conjuntos de compostos de ligação tendo rótulos moleculares liberáveis que são específicos para componentes múltiplos de um ou mais complexos formados dentro de trajetos apoptóticos. Depois da ligação, os rótulos moleculares são liberados e separados da mistura de ensaio para análise.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45988803P | 2003-04-01 | 2003-04-01 | |
| US10/623,057 US7105308B2 (en) | 2002-07-25 | 2003-07-17 | Detecting receptor oligomerization |
| US49448203P | 2003-08-11 | 2003-08-11 | |
| US50803403P | 2003-10-01 | 2003-10-01 | |
| US51294103P | 2003-10-20 | 2003-10-20 | |
| US52325803P | 2003-11-18 | 2003-11-18 | |
| PCT/US2004/009805 WO2004087887A2 (en) | 2003-04-01 | 2004-03-30 | Intracellular complexes as biomarkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0408928A true BRPI0408928A (pt) | 2006-09-12 |
Family
ID=33136354
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0408950-2A BRPI0408950A (pt) | 2003-04-01 | 2004-03-30 | método para determinar a situação de doença de um paciente, e, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica |
| BRPI0408961-8A BRPI0408961A (pt) | 2003-04-01 | 2004-03-30 | método para determinar uma situação de doença de um paciente, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica de erbb, e, método para determinar uma situação cancerosa de um paciente |
| BRPI0408928-6A BRPI0408928A (pt) | 2003-04-01 | 2004-03-30 | métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0408950-2A BRPI0408950A (pt) | 2003-04-01 | 2004-03-30 | método para determinar a situação de doença de um paciente, e, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica |
| BRPI0408961-8A BRPI0408961A (pt) | 2003-04-01 | 2004-03-30 | método para determinar uma situação de doença de um paciente, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica de erbb, e, método para determinar uma situação cancerosa de um paciente |
Country Status (6)
| Country | Link |
|---|---|
| EP (3) | EP1613205B1 (pt) |
| JP (2) | JP2006523314A (pt) |
| AU (3) | AU2004225439A1 (pt) |
| BR (3) | BRPI0408950A (pt) |
| CA (3) | CA2521106A1 (pt) |
| WO (3) | WO2004087887A2 (pt) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040229294A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
| EP1613205B1 (en) * | 2003-04-01 | 2013-04-24 | Monogram BioSciences, Inc. | Erbb surface receptor complexes as biomarkers |
| EP1673399B1 (en) * | 2003-08-11 | 2017-04-05 | Monogram BioSciences, Inc. | Detecting and profiling molecular complexes |
| US7402399B2 (en) * | 2003-10-14 | 2008-07-22 | Monogram Biosciences, Inc. | Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy |
| CA2580795A1 (en) * | 2004-09-22 | 2006-04-06 | Tripath Imaging, Inc. | Methods and compositions for evaluating breast cancer prognosis |
| US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| JP5025724B2 (ja) * | 2006-04-18 | 2012-09-12 | ウェルスタット バイオロジクス コーポレイション | 循環腫瘍性細胞からのタンパク質の検出 |
| WO2008019375A2 (en) * | 2006-08-07 | 2008-02-14 | The Board Of Regents Of The University Of Texas System | Proteomic patterns of cancer prognostic and predictive signatures |
| BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
| EP2097754B2 (en) | 2006-11-28 | 2018-01-24 | Daiichi Sankyo Europe GmbH | Activated her3 as a marker for predicting therapeutic efficacy |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| EP2179291B1 (en) * | 2007-07-13 | 2014-10-22 | Nestec S.A. | Drug selection for lung cancer therapy using antibody-based arrays |
| EP2235536A4 (en) * | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2-DIAGNOSTIC PROCEDURE |
| AU2009219437B2 (en) | 2008-02-25 | 2014-10-16 | Nestec S.A. | Drug selection for breast cancer therapy using antibody-based arrays |
| US8168755B2 (en) * | 2008-05-07 | 2012-05-01 | Eutropics Pharmaceuticals, Inc. | Antibodies specific to heterodimers of Bcl-2 family and uses thereof |
| WO2010019952A2 (en) * | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
| ES2637411T3 (es) | 2008-12-01 | 2017-10-13 | Laboratory Corporation Of America Holdings | Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95 |
| JP2012515353A (ja) * | 2009-01-15 | 2012-07-05 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | Ｈｅｒ−２発現の測定による患者の反応を判定する方法 |
| EP2387711B1 (en) | 2009-01-15 | 2015-04-22 | Laboratory Corporation of America Holdings | Methods of determining patient response by measurement of her-3 |
| AU2010229924B2 (en) | 2009-03-24 | 2016-07-21 | Plus Therapeutics Inc. | Devices and methods of cell capture and analysis |
| US20120100538A1 (en) | 2009-03-24 | 2012-04-26 | Biocept, Inc. | Devices and methods of cell capture and analysis |
| NZ596468A (en) | 2009-05-14 | 2013-11-29 | Nestec Sa | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
| JP5795311B2 (ja) | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 |
| EP2896632B1 (en) | 2009-11-13 | 2017-10-25 | Daiichi Sankyo Europe GmbH | Material and methods for treating or preventing HER-3 associated diseases |
| KR101798679B1 (ko) | 2010-03-11 | 2017-11-16 | 메리맥 파마슈티컬즈, 인크. | ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도 |
| US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
| US20140248291A1 (en) * | 2011-03-30 | 2014-09-04 | The Uab Research Foundation | Modulation of Cellular Migration |
| EP2751562B1 (en) | 2011-09-02 | 2015-09-16 | Nestec S.A. | Profiling of signal pathway proteins to determine therapeutic efficacy |
| WO2013192423A2 (en) | 2012-06-20 | 2013-12-27 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| US20160038503A1 (en) | 2012-11-21 | 2016-02-11 | David Richard | Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives |
| US20160041171A1 (en) * | 2013-04-05 | 2016-02-11 | Laboratory Corporation Of America Holdings | Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation |
| JP6478417B2 (ja) * | 2013-05-21 | 2019-03-06 | ダイアテック ホールディングス， インコーポレイテッドＤｉａＴｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｉｎｃ． | 大腸癌患者の生存を予測及び改善するための方法 |
| US10732182B2 (en) | 2013-08-01 | 2020-08-04 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
| JP6538044B2 (ja) | 2013-10-30 | 2019-07-03 | ユートロピクス ファーマシューティカルズ， インコーポレイテッド | 化学療法感受性および化学毒性を判定する方法 |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US10793915B2 (en) | 2015-01-12 | 2020-10-06 | Eutropics Pharmaceuticals, Inc. | Context dependent diagnostics test for guiding cancer treatment |
| US20190041389A1 (en) * | 2015-02-13 | 2019-02-07 | The University Of Queensland | Methods for classifying tumors and uses therefor |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| WO2017161030A1 (en) | 2016-03-15 | 2017-09-21 | Laboratory Corporation Of America Holdings | Methods of assessing protein interactions between cells |
| JPWO2019098385A1 (ja) * | 2017-11-20 | 2020-12-24 | コニカミノルタ株式会社 | 薬剤評価方法 |
| IT201800008274A1 (it) * | 2018-08-31 | 2020-03-02 | Alifax Srl | Metodo immunometrico per analisi cliniche biologiche |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| US5597531A (en) | 1985-10-04 | 1997-01-28 | Immunivest Corporation | Resuspendable coated magnetic particles and stable magnetic particle suspensions |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| CA2141451C (en) | 1992-07-31 | 2003-10-07 | John S. Pease | Photoactivatable chemiluminescent matrices |
| US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
| US6037134A (en) * | 1994-03-07 | 2000-03-14 | New York University Medical Center | Methods that detect compounds that disrupt receptor tyrosine kinase/GRB-7 complexes |
| US5693271A (en) | 1994-09-01 | 1997-12-02 | Chase Industries, Inc. | Rotationally molding an insulated plastic molded door with integral hinge |
| US5599631A (en) | 1995-03-08 | 1997-02-04 | Eastman Kodak Company | Fluorinated elastomer/fluorinated resin compositions for toner fusing members |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US6417168B1 (en) * | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
| US6095661A (en) | 1998-03-19 | 2000-08-01 | Ppt Vision, Inc. | Method and apparatus for an L.E.D. flashlight |
| WO2000014105A1 (en) * | 1998-09-08 | 2000-03-16 | Agouron Pharmaceuticals, Inc. | Modifications of the vegf receptor-2 protein and methods of use |
| US6514700B1 (en) * | 1999-04-30 | 2003-02-04 | Aclara Biosciences, Inc. | Nucleic acid detection using degradation of a tagged sequence |
| US6627400B1 (en) | 1999-04-30 | 2003-09-30 | Aclara Biosciences, Inc. | Multiplexed measurement of membrane protein populations |
| US6322980B1 (en) | 1999-04-30 | 2001-11-27 | Aclara Biosciences, Inc. | Single nucleotide detection using degradation of a fluorescent sequence |
| US6673550B2 (en) | 1999-04-30 | 2004-01-06 | Aclara Biosciences, Inc. | Electrophoretic tag reagents comprising fluorescent compounds |
| US6346384B1 (en) | 2000-03-27 | 2002-02-12 | Dade Behring Inc. | Real-time monitoring of PCR using LOCI |
| US7537938B2 (en) * | 2000-04-28 | 2009-05-26 | Monogram Biosciences, Inc. | Biomarker detection in circulating cells |
| EP1305632B1 (en) | 2000-05-04 | 2011-07-27 | Siemens Healthcare Diagnostics Products GmbH | Methods for detection of multiple analytes |
| US6547654B2 (en) | 2000-07-22 | 2003-04-15 | Americo Del Raso | Automatic abrasive sleeve tightening means and quick release system for an oscillating spindle sander |
| WO2002068668A2 (en) * | 2001-02-22 | 2002-09-06 | Immunex Corporation | Compositions and methods for production cell culture |
| CA2445053A1 (en) | 2001-05-21 | 2002-11-28 | Aclara Biosciences, Inc. | Methods and compositions for analyzing proteins |
| AU2002316577A1 (en) | 2001-07-09 | 2003-01-29 | Aclara Biosciences, Inc. | Cell-screening assay and composition |
| CA2354690A1 (en) | 2001-07-20 | 2001-10-27 | Jan Prinzmetal | Mat |
| US6545102B1 (en) * | 2001-09-27 | 2003-04-08 | Lumigen, Inc. | Polymer-supported photosensitizers |
| WO2003068808A1 (en) * | 2002-02-13 | 2003-08-21 | Garvan Institute Of Medical Research | Novel protein complexes and uses therefor |
| EP1654377A4 (en) * | 2002-03-01 | 2010-03-24 | Roger Williams Hospital | PROCESSES AND COMPOSITIONS RELATED TO THE SHC PROTEIN FOR THE PROGNOSIS OF BREAST, PROSTATE AND EGG CANCER |
| JP2006509183A (ja) * | 2002-03-05 | 2006-03-16 | アクララ バイオサイエンシーズ， インコーポレイテッド | 膜結合増感剤を用いる多重分析 |
| WO2004008099A2 (en) * | 2002-07-15 | 2004-01-22 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| JP4443407B2 (ja) | 2002-07-25 | 2010-03-31 | アクララ バイオサイエンシーズ， インコーポレイテッド | レセプターオリゴマー形成の検出 |
| EP1613205B1 (en) * | 2003-04-01 | 2013-04-24 | Monogram BioSciences, Inc. | Erbb surface receptor complexes as biomarkers |
| US7402399B2 (en) * | 2003-10-14 | 2008-07-22 | Monogram Biosciences, Inc. | Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy |
-
2004
- 2004-03-30 EP EP04759064.1A patent/EP1613205B1/en not_active Expired - Lifetime
- 2004-03-30 BR BRPI0408950-2A patent/BRPI0408950A/pt not_active IP Right Cessation
- 2004-03-30 AU AU2004225439A patent/AU2004225439A1/en not_active Abandoned
- 2004-03-30 CA CA002521106A patent/CA2521106A1/en not_active Abandoned
- 2004-03-30 WO PCT/US2004/009805 patent/WO2004087887A2/en not_active Ceased
- 2004-03-30 WO PCT/US2004/009715 patent/WO2004091384A2/en not_active Ceased
- 2004-03-30 AU AU2004230700A patent/AU2004230700A1/en not_active Abandoned
- 2004-03-30 BR BRPI0408961-8A patent/BRPI0408961A/pt not_active IP Right Cessation
- 2004-03-30 EP EP20040758577 patent/EP1613732A4/en not_active Withdrawn
- 2004-03-30 EP EP04759065A patent/EP1613961A4/en not_active Withdrawn
- 2004-03-30 JP JP2006509479A patent/JP2006523314A/ja active Pending
- 2004-03-30 JP JP2006509481A patent/JP2006521821A/ja active Pending
- 2004-03-30 WO PCT/US2004/009717 patent/WO2004092353A2/en not_active Ceased
- 2004-03-30 BR BRPI0408928-6A patent/BRPI0408928A/pt not_active IP Right Cessation
- 2004-03-30 AU AU2004229348A patent/AU2004229348A1/en not_active Abandoned
- 2004-03-30 CA CA002521077A patent/CA2521077A1/en not_active Abandoned
- 2004-03-30 CA CA002521082A patent/CA2521082A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2521077A1 (en) | 2004-10-28 |
| EP1613205A4 (en) | 2006-11-29 |
| AU2004225439A1 (en) | 2004-10-14 |
| WO2004091384A2 (en) | 2004-10-28 |
| EP1613961A2 (en) | 2006-01-11 |
| CA2521082A1 (en) | 2004-10-28 |
| WO2004087887A3 (en) | 2006-06-15 |
| EP1613205B1 (en) | 2013-04-24 |
| JP2006521821A (ja) | 2006-09-28 |
| AU2004230700A1 (en) | 2004-10-28 |
| CA2521106A1 (en) | 2004-10-14 |
| BRPI0408950A (pt) | 2006-03-28 |
| WO2004087887A2 (en) | 2004-10-14 |
| AU2004229348A1 (en) | 2004-10-28 |
| WO2004092353A3 (en) | 2005-03-03 |
| WO2004091384A3 (en) | 2005-12-29 |
| EP1613205A2 (en) | 2006-01-11 |
| EP1613961A4 (en) | 2007-03-07 |
| WO2004092353A2 (en) | 2004-10-28 |
| JP2006523314A (ja) | 2006-10-12 |
| EP1613732A4 (en) | 2012-03-14 |
| EP1613732A2 (en) | 2006-01-11 |
| BRPI0408961A (pt) | 2006-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0408928A (pt) | métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente | |
| BRPI0413471A (pt) | métodos para detectar um ou mais complexos de proteìnas e para detectar um complexo em uma amostra biológica | |
| Pan et al. | Dermal toxicity elicited by phthalates: evaluation of skin absorption, immunohistology, and functional proteomics | |
| EP1687283A4 (en) | FOR THE DETERMINATION OF FK506 PROCEDURE AND COMPOSITION | |
| Nakashima et al. | 4-Hydroxynonenal triggers multistep signal transduction cascades for suppression of cellular functions | |
| BR0009206A (pt) | Isolamento e análise de proteina | |
| EP2330219A3 (en) | Method for drug discovery, disease treatment and diagnosis using metabolomics | |
| ATE415631T1 (de) | AFFINITÄTSSCREENING MITTELS BIBLIOTHEKEN DES TYPS ßEINE-VERBINDUNG-PRO-KÜGELCHENß | |
| Raudensky et al. | Effects of chronic unpredictable stress and methamphetamine on hippocampal glutamate function | |
| BRPI0413495A (pt) | reagentes de peptìdeos especìficos para prìons e seus usos | |
| BR0115715A (pt) | Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata | |
| Malinowska et al. | Changes of blood platelet adhesion to collagen and fibrinogen induced by homocysteine and its thiolactone | |
| PT820303E (pt) | Analogos do peptido p277 e composicoes farmaceuticas que os compreendem, para tratamento ou diagnostico de diabetes | |
| EP1904043A4 (en) | METHOD AND COMPOSITION FOR THE TREATMENT OF SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND / OR SERUM RETINOL RBP MODULATION | |
| BR9811465A (pt) | N-triazolil-2-indolcarboxamidas e sua utilização como agonistas de cck-a. | |
| WO2004090154A3 (en) | Acyl- phosphate and phosphonate probes and methods of their synthesis and use in proteomic analysis | |
| Ringshausen et al. | Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL | |
| BRPI0415202A (pt) | método de eliciar uma resposta de célula t contra um epìtopo de célula t em um indivìduo mamìfero hospedeiro, ensaio para testar a eficácia de um método de eliciar uma resposta de célula t, e, kit para realizar os mesmos | |
| WO2003105773A3 (en) | Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets: | |
| Bernard et al. | Curcumin cross-links cystic fibrosis transmembrane conductance regulator (CFTR) polypeptides and potentiates CFTR channel activity by distinct mechanisms | |
| EP1546188A4 (en) | P53 BINDING T-CELL RECEPTOR MOLECULES AND THEIR USES | |
| Krizanova et al. | Capsaicin induces apoptosis in PC12 cells through ER stress | |
| Lin et al. | Analysis of oxidative and advanced oxidative modifications in hemoglobin of oral cancer patients by mass spectrometry | |
| WO2001088533A3 (en) | Lipid uptake assays | |
| Nagata et al. | D-serine content and D-[3H] serine binding in the brain regions of the senescence-accelerated mouse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |